$29.06+6.4%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
Company outlook: revenue of $875M to $900M for Fiscal year 2026 — down 6.0% on a year earlier ($943.7M)
Just reported
From Ionis Pharmaceuticals, Inc.'s results release of November 9, 2026; its quarterly report has since been filed.
Actual
$242.7M
+55% y/y
-9.4% q/q
Guided
—
No guide given
Actual
-$0.66
Guided
—
No guide given
Actual
-$130.7M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $242.7M | $156.7M | +54.88% |
| Profit | -$110M | -$128.6M | +14.49% |
| Profit per share | -$0.66 | -$0.80 | +17.50% |
| Free Cash Flow | -$192.1M | -$136.7M | -40.54% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Ionis Pharmaceuticals, Inc. reported on November 9, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“In 2026, we continue to advance innovative medicines for people with serious diseases, underscored by three approvals for groundbreaking first-in-class medicines, two of which are Ionis-owned,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from Ionis Pharmaceuticals, Inc.’s Item 2.02 8-K filed November 9, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.